Why the study?
What is the prevalence of neutralizing antibodies against AAV types 2, 5, and 6 in cystic fibrosis and normal populations?
Population
Children and adults with cystic fibrosis (CF), and normal adults
Design
Cross-sectional
Authors
Loading...
Supports AAV vector viability for CF lung gene therapy; leaves open prospective immunogenicity trials.
What is the prevalence of neutralizing antibodies against AAV types 2, 5, and 6 in cystic fibrosis and normal populations?
The low prevalence of neutralizing antibodies against AAV types 2, 5, and 6 in CF and control populations suggests these vectors may be viable for lung gene therapy.
Halbert et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: